Tin tức & Cập nhật

In the longer-term follow-up of the phase III AUGMENT trial, the lenalidomide-rituximab (R2) combination trumped the rituximab-placebo regimen (control) for the treatment of relapsed/refractory indolent non-Hodgkin lymphoma (R/R iNHL).

Local-control outcomes are encouraging in patients with osseous renal cell carcinoma metastases who went through five fractions of stereotactic body radiotherapy (SBRT), reports a study.

In the updated analysis of the phase III EMERALD trial, the next-generation oral SERD* elacestrant continued to show favourable signals for the treatment of ER+/HER2– metastatic breast cancer (mBC).

In the final overall survival (OS) analysis of the phase III PAOLA-1*/ENGOT-ov25 trial, the addition of olaparib to bevacizumab provided a survival benefit for women with newly diagnosed advanced ovarian cancer with HRD**-positive (HRD+) tumours.

In low- and middle-income countries (LMICs), there appears to be a long interval between the first onset of breast cancer symptoms and presentation to a healthcare provider, reports a recent study.

Human papillomavirus (HPV) self-sampling for cervical cancer screening is highly acceptable among Singaporean women, with the strategy deemed accurate and easy to perform, a study has found.